Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.31 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11119674 | 0.85 | HTR7 (0.36) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL3689833 | 0.82 | HCAR2 (0.41) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL3690825 | 0.80 | ALOX15 (0.35) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL5732065 | 0.80 | ALOX15 (0.35) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL151395 | 0.80 | HCAR2 (0.43) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL1437210 | 0.78 | TSHR (0.31) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL7425210 | 0.77 | HCAR2 (0.46) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL6898204 | 0.77 | HCAR2 (0.34) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL948656 | 0.74 | HCAR2 (0.49) | ALOX15TSHRKDM4EACMSDTDP1 | |
| SCHEMBL3794190 | 0.74 | GABRA1 (0.35) | KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| EP-1730128-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005097765-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | ALOX15 1840/4885TSHR 1413/4885KDM4E 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.